Ron Grunstein, MD, PhD, head of sleep and circadian research, Woolcock Institute of Medical Research, shares findings from a phase 1b study on the use of a novel orexin agonist in patients with narcolepsy type 1.
- Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations - -
Medical research institutes invited to apply for $160 million support manmonthly.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from manmonthly.com.au Daily Mail and Mail on Sunday newspapers.